GlassScriptPhysician profile
Christopher Lee Parman
NPI 1104807114
$3,573.11
in general payments reported to CMS, 2019-2025
23 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $386 · 2021: $505 · 2022: $229 · 2023: $172 · 2024: $352 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.63 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $870.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $486.37 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $483.39 | 2019-2024 | Farxiga, Airsupra |
| Antares Pharma, INC. | $350.89 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $245.50 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $214.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.67 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.76 | 2019-2021 | |
| Abbvie INC. | $58.17 | 2019-2023 | |
| Glaxosmithkline, LLC. | $57.90 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $53.92 | 2019-2021 | |
| Esperion Therapeutics, INC. | $38.01 | 2025 | Nexletol |
| Halozyme INC | $37.96 | 2023 | |
| Exact Sciences Corporation | $35.69 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.20 | 2019-2020 | |
| Boston Scientific Corporation | $26.07 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $25.83 | 2024 | Veozah |
| Eisai INC. | $25.76 | 2021 | |
| Qol Medical, LLC | $23.94 | 2022 | |
| Sanofi Pasteur INC. | $17.45 | 2020 | |
| Shire North American Group INC | $15.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Parman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.